	US 11,891,424 B2
	Methods and compositions for regenerating tissues
Cymbeline T. Culiat, Oak Ridge, TN (US)
Assigned to NellOne Therapeutics, Inc., Knoxville, TN (US)
Filed by NELLONE THERAPEUTICS, INC., Oak Ridge, TN (US)
Filed on May 28, 2021, as Appl. No. 17/333,406.
Application 17/333,406 is a division of application No. 16/813,376, filed on Mar. 9, 2020, granted, now 11,034,741.
Application 16/813,376 is a division of application No. 15/690,093, filed on Aug. 29, 2017, granted, now 10,752,663, issued on Aug. 25, 2020.
Claims priority of provisional application 62/380,920, filed on Aug. 29, 2016.
Prior Publication US 2021/0355179 A1, Nov. 18, 2021
Int. Cl. A61K 38/17 (2006.01); C07K 14/47 (2006.01)

CPC C07K 14/4705 (2013.01) [A61K 38/1709 (2013.01); C07K 14/47 (2013.01)]

43 Claims

1. A vector comprising a nucleic acid sequence encoding a NELL1 peptide fragment or variant thereof, having at least 95% sequence identity to SEQ ID NO: 17 or 18, wherein said NELL1 peptide fragment or variant thereof has at least one of the properties selected from the group consisting of:

a) enhanced efficacy in tissue regeneration,

b) enhanced promotion of wound healing,

c) easier purification,

d) higher yield, and

e) less aggregate formation,

when compared to the fragment's respective full-length NELL1 protein; and wherein said NELL1 peptide fragment or variant thereof lacks the carboxy-terminal 179 amino acid residues of the fragment's respective full-length NELL1 protein.